News archive search

Search the Newsreel

Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.

Showing
1–9
Matches
9
Sources here
8
Companies here
2
Search results Stored financial headlines

Active search

9 matching headlines

Ticker or company: MEDICOMain company stories
Clear

Search results

Matching headlines

External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.

KKR to Acquire Leading Multi-Specialty Healthcare Provider Medicover India

MUMBAI, India, August 06, 2026--(BUSINESS WIRE)--KKR, a leading global investment firm, today announced the signing of definitive agreements under which funds managed by KKR ("KKR") will acquire Medicover India, the India hospital operations (the "Company") of leading international healthcare and diagnostic services provider Medicover …

MCOV-B main company
Sharemaestro market context Trend signal active 52 weeks -13.3% · Next-week setup negative 44.9% MCOV-B stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Medico Remedies Ltd ਨੂੰ ਮਿਲੀ ₹13.38 ਕਰੋੜ ਦੀ ਡੋਮਿਨਿਕਨ ਰਿਪਬਲਿਕ ਸਰਕਾਰ ਤੋਂ ਸਪਲਾਈ ਆਰਡਰ

MEDICO main company
Sharemaestro market context Price above Trend Line 52 weeks +14.5% · Next-week setup negative 42.4% MEDICO stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Medicover AB (FRA:5M0B) Q2 2026 Earnings Call Highlights: Strong Organic Growth and Strategic ...

This article first appeared on GuruFocus. Organic Revenue Growth: 11.8%. Adjusted EBITA: 109.2%. Adjusted EBITDA Margin: 17.1%. Operating Cash Flow: Up 28.4% to 73.6%. Leverage: Reduced to 2.9% from 3.1% at year-end and 3.6% last year. Revenue in India: Up 23% in euros, 39.6% …

MCOV-B main company
Sharemaestro market context Trend signal active 52 weeks -13.3% · Next-week setup negative 44.9% MCOV-B stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Find financial news

Search the Newsreel

Use one field or combine several. Results are newest first.

Evidence context